UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):March 8, 2007 (March 8, 2007)
PAR PHARMACEUTICAL COMPANIES, INC.
(Exact name of registrant as specified in its charter)
| | | | | |
Delaware
(State or other jurisdiction of
incorporation or organization) | | File Number 1-10827
(Commission File Number) | | 22-3122182
(I.R.S. Employer
Identification No.) |
| | | |
300 Tice Boulevard, Woodcliff Lake, New Jersey
(Address of principal executive offices) | | 07677
(Zip Code) |
Registrant’s telephone number, including area code:(201) 802-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On March 8, 2007, Par Pharmaceutical Companies, Inc. (the “Company”) issued a press release announcing that Dr. Melvin Sharoky has been elected to the Company’s Board of Directors (the “Board”). Dr. Sharoky has served in several healthcare executive positions and currently serves as president and CEO of Somerset Pharmaceuticals, Inc., and as a director of Insmed, Inc., a biopharmaceutical company, and Learnwright, LLC, a private e-learning company. There are no arrangements or understandings between Dr. Sharoky and any other person pursuant to which he was selected as a director of the Company, and Dr. Sharoky has no reportable transactions under Item 404(a) of Regulation S-K. Dr. Sharoky will be entitled to the same compensation as other directors, as described in the Company’s most recent proxy statement filed with the SEC on April 13, 2006. The Company’s press release is furnished asExhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) The following exhibit is furnished with this Current Report on Form 8-K:
| | | | | |
| Exhibit No. | | Description |
| | 99.1 | | | Press Release dated March 8, 2007. |
Certain statements in this Current Report onForm 8-K constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent that any statements made in this Current Report onForm 8-K contain information that is not historical, such statements are essentially forward-looking and are subject to certain risks and uncertainties, including the risks and uncertainties discussed from time to time in the Company’s filings with the SEC, including its Annual Reports onForm 10-K, Quarterly Reports on Form 10-Q and Current Reports onForm 8-K. Any forward-looking statements included in this Current Report onForm 8-K are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Dated as of: March 8, 2007
| | | | | |
| | PAR PHARMACEUTICAL COMPANIES, INC.
(Registrant)
| |
| | /s/ Thomas Haughey | |
| | Name: | Thomas Haughey | |
| | Title: | Executive Vice President — General Counsel | |
EXHIBIT INDEX
The following exhibit is furnished with this Current Report on Form 8-K:
| | | | | |
| Exhibit No. | | Description |
| | 99.1 | | | Press Release dated March 8, 2007 |
